- Home
- NSP vs GLPG Comparison
NSP vs GLPG Comparison
Compare NSP & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSP
- GLPG
- Stock Information
- Founded
- NSP 1986
- GLPG 1999
- Country
- NSP United States
- GLPG Belgium
- Employees
- NSP N/A
- GLPG N/A
- Industry
- NSP Professional Services
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- NSP Consumer Discretionary
- GLPG Health Care
- Exchange
- NSP Nasdaq
- GLPG Nasdaq
- Market Cap
- NSP 2.0B
- GLPG 2.1B
- IPO Year
- NSP 1997
- GLPG 2005
- Fundamental
- Price
- NSP $49.05
- GLPG $35.55
- Analyst Decision
- NSP Hold
- GLPG Sell
- Analyst Count
- NSP 3
- GLPG 3
- Target Price
- NSP $58.33
- GLPG $26.00
- AVG Volume (30 Days)
- NSP 556.1K
- GLPG 182.1K
- Earning Date
- NSP 10-30-2025
- GLPG 10-29-2025
- Dividend Yield
- NSP 4.86%
- GLPG N/A
- EPS Growth
- NSP N/A
- GLPG N/A
- EPS
- NSP 1.05
- GLPG N/A
- Revenue
- NSP $6,695,000,000.00
- GLPG $323,674,692.00
- Revenue This Year
- NSP $5.06
- GLPG $1.77
- Revenue Next Year
- NSP $5.35
- GLPG $0.44
- P/E Ratio
- NSP $46.96
- GLPG N/A
- Revenue Growth
- NSP 2.40
- GLPG 5.43
- 52 Week Low
- NSP $44.14
- GLPG $22.36
- 52 Week High
- NSP $95.98
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- NSP 38.87
- GLPG 59.84
- Support Level
- NSP $47.99
- GLPG $32.37
- Resistance Level
- NSP $50.09
- GLPG $37.78
- Average True Range (ATR)
- NSP 1.57
- GLPG 0.85
- MACD
- NSP -0.06
- GLPG 0.32
- Stochastic Oscillator
- NSP 16.13
- GLPG 62.33
About NSP Insperity Inc.
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.